[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

North America POCT Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

October 2017 | 150 pages | ID: N4E9C8C7E4EEN
Data Bridge Market Research

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
In this region, North America Point-Of-Care Testing market is projected to reach USD 17,823.81 million by 2024, from USD 9,601.74 million in 2016 growing at a CAGR of 8.0% in the forecast period 2017 to 2024
Based on geography, the North America point-of-care testing market is segmented into 3 geographical regions, such as,
  • U.S.
  • Mexico
  • Canada
North America point-of-care testing market competition by top players including

F. Hoffmann-La Roche Ltd is going to dominate the Point-Of-Care Testing market following with Siemens AG and Abbott Laboratories, Inc., along with others such as
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Johnson & Johnson, Alere Inc.
  • Instrumentation Laboratory
  • PTS Diagnostics, Abaxis, Inc.
  • Medtronic, Accriva Diagnostics
  • OPTI Medical, Sienco, Inc.
  • Alpha Scientific
  • AccuBioTech Co., Ltd.
  • ACON Laboratories, Inc.
  • Acrongenomics, Inc.
  • bioMérieux SA
  • Biomerica, Inc.
  • Atlas Genetics Ltd.
  • Alfa Scientific Designs, Inc.
  • Bio-Rad Laboratories, Inc.
  • Medica Corporation
  • Nova Biomedica.
The North America point-of-care testing market is segmented on the basis of product into prescription mode, distribution channel, end user, and geography.

On the basis of product, the market is segmented into 13 major segments, which includes blood glucose testing kits, cardiometabolic monitoring kits, infectious disease testing kits, cholesterol testing kits, pregnancy and fertility tests kits, tumor/cancer markers, urinalysis testing kits, cholesterol test strips, hematology testing kits, drugs of abuse testing kits, fecal occult testing kits, rapid coagulation testing kits, and others.

Cardiometabolic Monitoring Kits are further segmented into cardiac markers, blood gas/electrolytes testing kits, HbA1c testing kits, and lipids testing. Also, infectious disease testing kits are further segmented into influenza testing kits, HIV testing kits, hepatitis C testing kits, sexually-transmitted diseases testing kits, tropical diseases testing kits, healthcare-associated infections), and respiratory infections testing kit. Cholesterol testing kits are further divided into prothrombin time testing kits and activated clotting time testing kit.

Based on prescription mode, the North America point-of-care testing market is segmented into prescription based testing and over-the-counter (OTC) testing.

On the basis of distribution channel, the market is segmented into direct tenders and retail.

On the basis of end users, the market is segmented into hospital, clinics, ambulatory care, home healthcare, and research laboratory. Hospital segment is further categorized into emergency department critical-care unit, general ward, and others (intensive care unit, neo-natal). Also, clinic is segmented into physicians’ clinic and diagnostic clinic.
1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF NORTH AMERICA POINT-OF-CARE TESTING MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURC
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS
  3.1.1. GROWING GERIATRIC POPULATION
  3.1.2. ADVANCEMENT IN TECHNOLOGY
  3.1.3. DECENTRALIZED LABORATORY TESTING
  3.1.4. INCREASED INCIDENCE OF CHRONIC DISEASES
  3.1.5. LABORATORY STAFF SHORTAGES
3.2. RESTRAINTS
  3.2.1. UNFAVOURABLE REIMBURSEMENT SCENARIO
  3.2.2. ECONOMIC COST
3.3. OPPORTUNITIES
  3.3.1. EMERGING MICROFLUIDIC LAB-ON-A-CHIP TECHNOLOGY
  3.3.2. EMERGING MARKETS
  3.3.3. UNMET MEDICAL NEEDS
3.4. CHALLENGES
  3.4.1. LACK OF ACCURACY AND EFFICIENCY
  3.4.2. DATA MANAGEMENT AND LACK OF CONNECTIVITY
  3.4.3. TESTING PERFORMED BY NON-LABORATORY PERSONNEL AND LACK OF AWARENESS AMONG THE USERS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. NORTH AMERICA POINT-OF-CARE TESTING MARKET: REGULATORY SCENARIO

6.1. OVERVIEW:
  6.1.1. REGULATORY PROCEDURE:

7. NORTH AMERICA POINT-OF-CARE TESTING MARKET: REIMBURSEMENT SCENARIO

7.1. OVERVIEW:

8. NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE

8.1. OVERVIEW
8.2. CARDIOMETABOLIC MONITORING KITS
  8.2.1. CARDIAC MARKERS
  8.2.2. BLOOD GAS ELECTROLYTE TESTING KITS
  8.2.3. HBA1C TESTING KITS
  8.2.4. LIPID TESTING KITS
8.3. INFECTIOUS DISEASE TESTING KITS
  8.3.1. INFLUENZA TESTING KITS
  8.3.2. HIV TESTING KITS
  8.3.3. HEPATITIS TESTING KITS
  8.3.4. STD TESTING KITS
  8.3.5. TROPICAL DISEASESTESTING KITS
  8.3.6. HEALTHCARE ASSOCIATED TESTING KITS
  8.3.7. RESPIRATORY INFECTIONS TESTING KITS
8.4. CHOLESTEROL TESTING KITS
  8.4.1. PROTHROMBIN TIME TESTING KITS
  8.4.2. ACTIVATED CLOTTING TIME TESTING KITS
8.5. BLOOD GLUCOSE TESTING KITS
8.6. PREGNANCY AND FERTILITY TESTING KITS
8.7. TUMOR CANCER MARKERS
8.8. URINALYSIS TESTING KITS
8.9. HEMATOLOGY TESTING KITS
8.10. DRUGS OF ABUSE TESTING KITS
8.11. FECAL OCCULT TESTING KITS
8.12. RAPID COAGULATION TESTING KITS

9. NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL

9.1. OVERVIEW
  9.1.1. DIRECT TENDER
  9.1.2. RETAIL PHARMACY

10. NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY END USER

10.1. OVERVIEW
10.2. NORTH AMERICA POCT MARKET: HOSPITALS
10.3. NORTH AMERICA POCT MARKET: CLINICS
10.4. NORTH AMERICA POCT MARKET: AMBULATORY CARE
10.5. NORTH AMERICA POCT MARKET: HOME HEALTHCARE
10.6. NORTH AMERICA POCT MARKET: RESEARCH LABORATORIES

11. NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE

11.1. OVERVIEW
11.2. NORTH AMERICA POCT MARKET: PRESCRIPTION BASED TESTING KITS
11.3. NORTH AMERICA POCT MARKET: OVER THE COUNTER BASED TESTING KITS

12. NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY

12.1. OVERVIEW
12.2. NORTH AMERICA POINT-OF-CARE TESTING MARKET
  12.2.1. U.S.POINT-OF-CARE TESTING MARKET
  12.2.2. CANADA POINT-OF-CARE TESTING MARKET
  12.2.3. MEXICO POINT-OF-CARE TESTING MARKET

13. NORTH AMERICA POINT-OF-CARE TESTING MARKET: COMPANY LANDSCAPE

13.1. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

14.1. JOHNSON AND JOHNSON SERVICES, INC.
  14.1.1. COMPANY OVERVIEW
  14.1.2. REVENUE ANALYSIS
  14.1.3. PRODUCT PORTFOLIO
  14.1.4. RECENT DEVELOPMENTS
14.2. BECTON, DICKINSON AND COMPANY
  14.2.1. COMPANY OVERVIEW
  14.2.2. REVENUE ANALYSIS
  14.2.3. PRODUCT PORTFOLIO
  14.2.4. RECENT DEVELOPMENTS
14.3. MEDTRONIC
  14.3.1. COMPANY OVERVIEW
  14.3.2. REVENUE ANALYSIS
  14.3.3. PRODUCT PORTFOLIO
  14.3.4. RECENT DEVELOPMENTS
14.4. F. HOFFMANN-LA ROCHE LTD
  14.4.1. COMPANY OVERVIEW
  14.4.2. REVENUE ANALYSIS
  14.4.3. PRODUCT PORTFOLIO
  14.4.4. RECENT DEVELOPMENTS
14.5. SIEMENS AG
  14.5.1. COMPANY OVERVIEW
  14.5.2. REVENUE ANALYSIS
  14.5.3. PRODUCT PORTFOLIO
  14.5.4. RECENT DEVELOPMENTS
14.6. ABBOTT
  14.6.1. COMPANY OVERVIEW
  14.6.2. REVENUE ANALYSIS
  14.6.3. PRODUCT PORTFOLIO
  14.6.4. PRODUCT PIPELINE
  14.6.5. RECENT DEVELOPMENTS
14.7. DANAHER
  14.7.1. COMPANY OVERVIEW
  14.7.2. REVENUE ANALYSIS
  14.7.3. PRODUCT PORTFOLIO
  14.7.4. RECENT DEVELOPMENTS
14.8. WERFENLIFE
  14.8.1. COMPANY OVERVIEW
  14.8.2. REVENUE ANALYSIS
  14.8.3. PRODUCT PORTFOLIO
  14.8.4. RECENT DEVELOPMENTS
14.9. HENRY SCHEIN, INC.
  14.9.1. COMPANY OVERVIEW
  14.9.2. REVENUE ANALYSIS
  14.9.3. PRODUCT PORTFOLIO
  14.9.4. RECENT DEVELOPMENTS
14.10. OPTI MEDICAL (SUBSIDIARY OF IDEXX LABORATORIES, INC)
  14.10.1. COMPANY OVERVIEW
  14.10.2. REVENUE ANALYSIS
  14.10.3. PRODUCT PORTFOLIO
  14.10.4. RECENT DEVELOPMENTS
14.11. SIENCO, INC.
  14.11.1. COMPANY OVERVIEW
  14.11.2. REVENUE ANALYSIS
  14.11.3. PRODUCT PORTFOLIO
  14.11.4. RECENT DEVELOPMENTS
14.12. ACON LABORATORIES, INC.
  14.12.1. COMPANY OVERVIEW
  14.12.2. REVENUE ANALYSIS
  14.12.3. PRODUCT PORTFOLIO
  14.12.4. RECENT DEVELOPMENTS
14.13. ATIVA MEDICAL CORPORATION
  14.13.1. COMPANY OVERVIEW
  14.13.2. REVENUE ANALYSIS
  14.13.3. PRODUCT PORTFOLIO
  14.13.4. RECENT DEVELOPMENTS
14.14. ABAXIS
  14.14.1. COMPANY OVERVIEW
  14.14.2. REVENUE ANALYSIS
  14.14.3. PRODUCT PORTFOLIO
  14.14.4. RECENT DEVELOPMENTS
14.15. ARKRAY, INC
  14.15.1. COMPANY OVERVIEW
  14.15.2. REVENUE ANALYSIS
  14.15.3. PRODUCT PORTFOLIO
  14.15.4. RECENT DEVELOPMENTS
14.16. AERSCHER DIAGNOSTICS, LLC
  14.16.1. COMPANY OVERVIEW
  14.16.2. REVENUE ANALYSIS
  14.16.3. PRODUCT PORTFOLIO
  14.16.4. RECENT DEVELOPMENTS
14.17. ARTRON LABORATORIES, INC.
  14.17.1. COMPANY OVERVIEW
  14.17.2. REVENUE ANALYSIS
  14.17.3. PRODUCT PORTFOLIO
  14.17.4. RECENT DEVELOPMENTS
14.18. BIOMERIEUX SA
  14.18.1. COMPANY OVERVIEW
  14.18.2. REVENUE ANALYSIS
  14.18.3. PRODUCT PORTFOLIO
  14.18.4. RECENT DEVELOPMENTS
14.19. ENTOPSIS
  14.19.1. COMPANY OVERVIEW
  14.19.2. REVENUE ANALYSIS
  14.19.3. PRODUCT PORTFOLIO
  14.19.4. RECENT DEVELOPMENTS
14.20. LIFESIGN, LLC.
  14.20.1. COMPANY OVERVIEW
  14.20.2. REVENUE ANALYSIS
  14.20.3. PRODUCT PORTFOLIO
  14.20.4. RECENT DEVELOPMENTS

15. RELATED REPORTS

LIST OF TABLES

TABLE 1 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
TABLE 2 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
TABLE 3 NORTH AMERICA CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
TABLE 4 NORTH AMERICA INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024(USD MILLION)
TABLE 5 NORTH AMERICA CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024(USD MILLION)
TABLE 6 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE 2015 – 2024 (USD MILLION)
TABLE 7 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)
TABLE 8 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)
TABLE 9 U.S.POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
TABLE 10 U.S. POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)
TABLE 11 U.S. POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)
TABLE 12 U.S. POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)
TABLE 13 CANADA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 14 CANADA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)
TABLE 15 CANADA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)
TABLE 16 CANADA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)
TABLE 17 MEXICO POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 18 MEXICO POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)
TABLE 19 MEXICO POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)
TABLE 20 MEXICO POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

LIST OF FIGURES

FIGURE 1 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR POINT-OF-CARE TESTINGIN 2016 AND APAC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD TO 2024
FIGURE 2 NORTH AMERICA IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR POINT-OF-CARE TESTING MANUFACTURERS IN THE FORECAST PERIOD TO 2024
FIGURE 3 NORTH AMERICA POINT-OF-CARE TESTING MARKET SNAPSHOT (2017)
FIGURE 4 NORTH AMERICA POINT-OF-CARE TESTING MARKET: BY COUNTRY (2017)
FIGURE 5 NORTH AMERICA POINT-OF-CARE TESTING MARKET BY COUNTRY (2016 & 2024)
FIGURE 6 NORTH AMERICA POINT-OF-CARE TESTING MARKET BY PRODUCT TYPE (2017 & 2024)
FIGURE 7 NORTH AMERICA POINT-OF-CARE TESTING MARKET: COMPANY SHARE 2016 (%)


More Publications